Variable at presentation | Odds ratio estimate (95% confidence limits) | ||
---|---|---|---|
Model A | Model B | Model C | |
RF ≥ 40 IU/ml | 1.788 (0.549–5.825) | 2.946 (0.957–9.073) | 2.110 (0.715–6.231) |
Anti-CCP ≥ 20 U/ml | 0.320 (0.075–1.357) | 0.917 (0.285–2.953) | - |
Anti-Sa-positive | 8.832 (2.141–36.436)*** | - | - |
Anti-CCP ≥ 60 U/ml | - | - | 1.693 (0.551–5.201) |
Age (per year) | 1.063 (1.025–1.102)*** | 1.049 (1.015–1.084)*** | 1.048 (1.014–1.084)*** |
Male sex | 1.741 (0.718–4.223) | 1.627 (0.703–3.767) | 1.700 (0.733–3.945) |
Disease duration | 1.686 (0.701–4.058) | 1.647 (0.715–3.793) | 1.603 (0.700–3.673) |
Morning stiffness | 0.415 (0.154–1.118) | 0.554 (0.218–1.406) | 0.502 (0.196–1.284) |
Symmetry of arthritis | 0.798 (0.174–3.657) | 1.085 (0.241–4.880) | 1.315 (0.282–6.124) |
Swollen joint count | 0.985 (0.940–1.033) | 0.989 (0.946–1.033) | 0.988 (0.945–1.033) |
M-HAQ ≥ 1.0 | 0.666 (0.266–1.666) | 0.750 (0.315–1.789) | 0.791 (0.330–1.897) |
CRP ≥ 8 mg/L | 2.594 (0.920–7.312) | 2.107 (0.795–5.581) | 2.139 (0.807–5.667) |
HLA shared epitope | 1.096 (0.444–2.704) | 0.982 (0.417–2.313) | 0.937 (0.401–2.186) |
Erosion SvH score | 3.472 (1.236–9.575)* | 3.751 (1.388–10.135)* | 3.611 (1.340–9.729)** |